MARKET

XBIT

XBIT

XBiotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.32
-0.27
-1.85%
Closed 16:00 09/24 EDT
OPEN
14.64
PREV CLOSE
14.59
HIGH
14.99
LOW
14.25
VOLUME
97.01K
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
12.92
MARKET CAP
435.02M
P/E (TTM)
-35.1153
1D
5D
1M
3M
1Y
5Y
Xbiotech Inc (XBIT) CEO John Simard Sold $757,500 of Shares
GuruFocus News · 3d ago
XBiotech's (NASDAQ:XBIT) investors will be pleased with their fantastic 514% return over the last three years
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
Simply Wall St. · 09/14 15:48
XBiotech Says Dr. Benjamin Musher To Chair Phase 1-2 Study Evaluating Co's Natrunix Anti-Cancer Therapy In Pancreatic Cancer
 XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech's clinical program for pancreatic cancer. The Company is developing a novel cancer drug,
Benzinga · 09/08 13:15
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech's Natrunix(TM) Anti-Cancer Therapy in Pancreatic Cancer
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) ("XBiotech") today announced that Benjamin Musher M.D., will chair XBiotech's clinical program for pancreatic cancer. The Company is developing a novel cancer drug, Natrunix(T...
Globe Newswire · 09/08 13:00
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director
Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple IndicationsAUSTIN, Texas, Aug. 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the addition of Mark Ziats, M.D. Ph.D....
GlobeNewswire · 08/30 13:00
--XBiotech Pays Dividend of $2.47 a Share July 23 to Shareholders of Record on July 16
MT Newswires · 07/30 15:59
XBiotech Announces Payment of Dividend to Holders of Common Stock
Company distributed USD $75 Million to Shareholders
Globe Newswire · 07/30 15:03
Insider Trends: Xbiotech Insider Extends 90-Day Selling Trend
MT Newswires · 07/19 14:42
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XBIT. Analyze the recent business situations of XBiotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XBIT stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 4.14M
% Owned: 13.64%
Shares Outstanding: 30.38M
TypeInstitutionsShares
Increased
19
325.61K
New
2
13.55K
Decreased
24
408.15K
Sold Out
11
146.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
John Simard
Chief Scientific Officer
Sushma Shivaswamy
Vice President - Finance/Director of Human Resources/Secretary
Queena Han
Lead Director/Independent Director
Jan-Paul Waldin
Independent Director
Peter Libby
Independent Director
Donald Macadam
Independent Director
W. Thorpe McKenzie
Declaration Date
Dividend Per Share
Ex-Div Date
07/06/2021
Special Dividend USD 2.0995
07/15/2021
About XBIT
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Webull offers kinds of XBiotech Inc stock information, including NASDAQ:XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.